Clinical trial
A Phase III Study to Assess the Efficacy and Safety of Ralfinamide.
NCT01019824 is registered in ClinicalTrials.gov with Newron Pharmaceuticals SPA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Study to Assess the Efficacy and Safety of Ralfinamide.
- Lead sponsor
- Newron Pharmaceuticals SPA
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 20, 2009
- Completion date
- August 9, 2011
- Enrollment
- 411 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.